ENSYSCE BIOSCIENCES, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-12-31 was $0.00.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-09-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-06-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was $1.17M, a 61.77% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $1.17M, a 61.77% decline from fiscal 2023.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $3.06M, a 85.77% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $21.49M, a 277.16% increase from fiscal 2021.
- ENSYSCE BIOSCIENCES, INC. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $5.70M, a 469.67% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.17M 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.17M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.17M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-13 | $1.17M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.06M 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.67M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $10.75M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $3.06M 10-Q · filed 2024-05-13 | $16.47M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $21.49M 10-K · filed 2024-03-15 |
| 2022-09-30 | $4.07M 10-Q · filed 2023-11-09 | $17.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.72M 10-Q · filed 2023-08-11 | $13.79M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $8.08M 10-Q · filed 2023-05-15 | $13.77M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $5.70M 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $5.70M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $1.00M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |